Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial
Lists
Only you see this
Abstract
SARS-CoV-2 vaccine-boosted participants had the least severe symptoms during COVID-19, which abated the quickest over time. Clinical Trial Registration. NCT04510194.
BibTeX
@inproceedings{boulware2022impact,
author = {David R. Boulware and Thomas A. Murray and Jennifer Proper and Christopher J. Tignanelli and John B. Buse and David Liebovitz and Jacinda M. Nicklas and Kenneth J. Cohen and Michael A. Puskarich and Hrishikesh Belani and Lianne Siegel and Nichole R. Klatt and David J. Odde and Amy B. Karger and Nicholas E. Ingraham and Katrina M Hartman and Via Rao and Aubrey A Hagen and Barkha Patel and Sarah L. Fenno and Nandini Avula and Neha V Reddy and Spencer M Erickson and Sarah Lindberg and Regina Fricton and Samuel Lee and Adnin Zaman and Hanna G Saveraid and Walker Tordsen and Matthew F Pullen and Nancy E. Sherwood and Jared D. Huling and Carolyn T. Bramante and for the COVID-OUT study team},
title = {{Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial}},
booktitle = {Clinical},
year = {2022},
doi = {10.1093/cid/ciac772},
}Loading related content...